amisulpride antiemetic antipsychotic medication used lower doses intravenously prevent treat postoperative nausea vomiting higher doses mouth treat schizophrenia acute psychotic episodes sold brand names antiemetic solian socian deniban others low doses also used treat usually classed atypical antipsychotics chemically benzamide like benzamide antipsychotics sulpiride associated high risk elevating blood levels lactation hormone prolactin thereby potentially causing absence menstrual cycle breast enlargement even males breast milk secretion related breastfeeding impaired fertility impotence breast pain etc low risk relative typical antipsychotics causing movement amisulpride indicated use united states adults prevention postoperative nausea vomiting ponv either alone combination antiemetic different class treat ponv received antiemetic prophylaxis agent different class received amisulpride believed work blocking antagonizing dopamine receptor reducing signalling effectiveness amisulpride treating dysthymia negative symptoms schizophrenia believed stem blockade presynaptic dopamine receptors presynaptic receptors regulate release dopamine synapse blocking amisulpride increases dopamine concentrations synapse increased dopamine concentration theorized act dopamine receptors relieve depressive symptoms dysthymia negative symptoms introduced sanofiaventis patent expired generic formulations became marketed englishspeaking countries except although according studies appears comparable efficacy olanzapine treatment amisulpride augmentation similarly sulpiride augmentation considered viable treatment option although based lowquality evidence clozapineresistant cases another recent study concluded amisulpride appropriate firstline treatment management acute amisulpride indicated use united states adults prevention postoperative nausea vomiting ponv either alone combination antiemetic different class treat ponv received antiemetic prophylaxis agent different class received amisulprides use contraindicated following disease states neither recommended use amisulpride patients hypersensitivities amisulpride excipients found dosage hyperprolactinaemia results antagonism receptors located lactotrophic cells found anterior pituitary gland amisulpride high propensity elevating plasma prolactin levels result poor barrier penetrability hence resulting greater ratio peripheral occupancy central occupancy means achieve sufficient occupancy central receptors order elicit therapeutic effects dose must given enough saturate peripheral receptors including anterior british national formulary recommends gradual withdrawal discontinuing antipsychotics avoid acute withdrawal syndrome rapid symptoms withdrawal commonly include nausea vomiting loss symptoms may include restlessness increased sweating trouble less commonly may feeling world spinning numbness muscle symptoms generally resolve short period tentative evidence discontinuation antipsychotics result may also result reoccurrence condition rarely tardive dyskinesia occur medication torsades de pointes common amisulpride moderately dangerous overdose tcas dangerous ssris modestly amisulpride used conjunction drugs prolong qt interval citalopram bupropion clozapine tricyclic antidepressants sertindole ziprasidone reduce heart rate induce hypokalaemia likewise imprudent combine antipsychotics due additive risk tardive dyskinesia neuroleptic malignant amisulpride functions primarily dopamine receptor antagonist high affinity receptors dissociation constants nm although standard doses used treat psychosis inhibit dopaminergic neurotransmission low doses preferentially block inhibitory presynaptic autoreceptors results facilitation dopamine activity reason lowdose amisulpride also used treat amisulpride relatives sulpiride levosulpiride sultopride shown bind highaffinity ghb receptor concentrations therapeutically relevant halfmaximal inhibitory concentration nm amisulpride sultopride sulpiride respectively present decreasing vitro affinities receptor nm receptor though long widely assumed dopaminergic modulation solely responsible respective antidepressant antipsychotic properties amisulpride subsequently found drug also acts potent antagonist serotonin receptor ki several atypical antipsychotics risperidone ziprasidone potent antagonists receptor well selective antagonists receptor show antidepressant properties characterize role receptor antidepressant effects amisulpride study prepared receptor knockout study found two widely used rodent models depression tail suspension test forced swim test mice exhibit antidepressant response upon treatment results suggest receptor antagonism mediates antidepressant effects amisulpride also appears bind high affinity serotonin receptor ki nm acts clinical implications case evidence action mediates therapeutic effects amisulpride shows stereoselectivity aramisulpride ramisulpride higher affinity receptor ki nm vs nm esamisulpride samisulpride higher affinity receptor nm vs ratio aramisulpride esamisulpride provides balanced receptor antagonism racemic amisulpride ratio enantiomers development treatment bipolar high direct unmetabolized excretion despite high usual dose also high affinity also available literature gives us hints also relatively high receptor dissocitation kinetics delayed high occupancy dopaminereceptors hours mg exposure moreover dopamine exposure could slightly balanced preventing little advantages haloperidol using drug exposure due lack compensatory serotonin effects also anticholinergic profile may considered effective alternative akathasia brand names include amazeo amipride au amival solian au ie ru uk za soltus sulpitac sulprix au midora ro socian amisulpride approved food drug administration use united states psychiatric indications approved use throughout asia mexico new zealand treat psychosis iv formulation amisulpride approved treatment postoperative nausea vomiting ponv united states february us food drug administration fda approved amisulpride iv formulation use postoperative nausea based evidence four clinical trials subjects undergoing surgery experiencing nausea vomiting trials conducted sites united states canada two trials trials enrolled subjects scheduled subjects randomly assigned receive either amisulpride placebo drug beginning general trial subjects received amisulpride placebo alone trial received amisulpride placebo combination one medication approved prevention nausea neither subjects health care providers knew treatment given trial trials counted number subjects vomiting use additional medications nausea vomiting first day hours results compared amisulpride two trials trials enrolled subjects experiencing nausea vomiting trial subjects receive medication prevent nausea vomiting surgery trial received medication treatment trials subjects randomly assigned receive either amisulpride neither subjects health care providers knew treatment given trial trials counted number subjects vomiting use additional medications nausea vomiting first day hours trial compared amisulpride fda approved amisulpride use psychiatric indication lb pharmaceuticals developing nmethyl amisulpride use treatment schizophrenia phase firstinpatient study planned httpsenwikipediaorgwikiamisulpride